<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393600</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-98854-1101</org_study_id>
    <nct_id>NCT01393600</nct_id>
  </id_info>
  <brief_title>NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Cross-Over Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses
      (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive
      dyskinesia in subjects with schizophrenia or schizoaffective disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of 12.5 or 50 mg doses of NBI-98854 administered once daily for the treatment of tardive dyskinesia (TD) symptoms</measure>
    <time_frame>28 days</time_frame>
    <description>Abnormal Involuntary Movements Scale (AIMS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of 12.5 or 50 mg doses of NBI-98854 administered once daily for the treatment of tardive dyskinesia (TD) symptoms</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical Global Impression of Tardive Dyskinesia (CGI-TD) and a Patient Global Impression of Change (PGIC) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events following dosing with NBI-98854</measure>
    <time_frame>35 days</time_frame>
    <description>Safety and tolerability monitoring will include the following assessments:
Adverse Events
Clinical lab tests (hematology, serum chemistry, and urinalysis)
Vital signs
Physical examinations
12-lead electrocardiograms (ECG)
Brief Psychiatric Rating Scale (BPRS)
Columbia Suicide Severity Rating Scale (C-SSRS)
Calgary Depression Scale for Schizophrenia (CDSS)
Barnes Akathisia Rating Scale (BARS)
Simpson-Angus Scale (SAS)
Serum Prolactin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of plasma exposure measures of NBI-98854 following repeated daily doses (12.5 and 50 mg) of NBI-98854.</measure>
    <time_frame>35 days</time_frame>
    <description>Blood samples will be collected and analyzed to evaluate drug and metabolite plasma concentrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Tardive Dyskinesia</condition>
  <arm_group>
    <arm_group_label>NBI-98854 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.
Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBI-98854 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.
Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-98854</intervention_name>
    <description>12.5 mg powder in bottle once daily for 14 days</description>
    <arm_group_label>NBI-98854 12.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-98854</intervention_name>
    <description>50 mg powder in bottle once daily for 14 days</description>
    <arm_group_label>NBI-98854 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution containing no active substance</description>
    <arm_group_label>NBI-98854 12.5 mg</arm_group_label>
    <arm_group_label>NBI-98854 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a clinical diagnosis of schizophrenia or schizoaffective disorder and a clinical
             diagnosis of neuroleptic-induced tardive dyskinesia as defined in the Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition (DSM-IV), 333.82 (see Appendix
             17.1) for at least 3 months prior to screening.

          -  Be receiving a stable dose of antipsychotic medication for a minimum of 30 days
             before study start. Subjects who are not using antipsychotic medication must have
             stable psychiatric status.

          -  Have the doses of concurrent medications and the conditions being treated be stable
             for a minimum of 30 days before study start and be expected to remain stable during
             the study.

          -  Subjects of childbearing potential must agree to use hormonal or two forms of
             nonhormonal birth control during the study.

          -  Female subjects must not be pregnant.

          -  Be in good general health and expected to complete the clinical study as designed.

          -  Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).

          -  Have adequate hearing, vision, and language skills to perform the procedures
             specified in the protocol.

          -  Have a negative urine drug screen (negative for amphetamines, barbiturates,
             benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and
             study start, except for any subject receiving a stable dose of benzodiazepine.

          -  Have a negative alcohol breath test at screening and study start.

        Exclusion Criteria:

          -  Have an active clinically significant unstable medical condition within 1 month (30
             days) prior to screening.

          -  Have a history of substance dependence or substance (drug) or alcohol abuse within
             the 3 months before study start(nicotine and caffeine dependence are not
             exclusionary).

          -  Have a known history of neuroleptic malignant syndrome.

          -  Have a significant risk of suicidal or violent behavior.

          -  Receiving any excluded concomitant medication such as reserpine, metoclopramide,
             stimulants, or tetrabenazine

          -  Receiving medication for the treatment of tardive dyskinesia.

          -  Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface
             antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a
             history of positive result.

          -  Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study.

          -  Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

          -  Have had previous exposure with NBI-98854.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher O'Brien, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurocrine Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woodland International Research Group, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Outpatient Psychiatry</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCSD - Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Marseilles</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>July 11, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>April 30, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
